Meeting
2020 Gastrointestinal Cancers Symposium
Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.
Authors
Mark D. Sternlicht
FibroGen, Inc., San Francisco, CA
Mark D. Sternlicht , Dongxia Li , Viet-Tam Nguyen , Mairead Carney , Duo Zhou , Kenneth E. Lipson , Elias Kouchakji , Vincent J. Picozzi , Ewa Carrier , Todd W. Seeley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 752)
Abstract #
752
Poster Bd #
M19
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
First Author: Vincent J. Picozzi
Poster
2014 ASCO Annual Meeting
FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Vincent J. Picozzi
Poster
2013 Gastrointestinal Cancers Symposium
FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Vincent Picozzi
Poster
2023 ASCO Genitourinary Cancers Symposium
Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).
First Author: Aitzaz Qaisar